CYP2J2 is a member of the cytochrome P450 (CYP) family of monooxygenases, and, in humans, is the sole member of the CYP2J subfamily [1] . Specifically, CYP2J2 is an epoxygenasethat catalyzes epoxideformation at thesite of a carbon-carbon double bond in the substrate, as other CYP epoxygenases do, such as CYP2C8 and CYP2C9 [2] . The therapeutic agents ebastine [3] , astemizole, terfenadine, diclofenac, and bufurarol are metabolized by CYP2J2 [4] . A recent study, screening 139 marketed therapeutic agents and compounds, have identified albendazole, amiodarone, cyclosporine A, danazol, mesoridazine, nabumetone, tamoxifen, and thioridazine as CYP2J2 substrates [5] . These findings show the ability of CYP2J2 to metabolize structurally diverse compounds. The substrates identified for CYP2J2 were also metabolized by CYP3A4, but with differences in regioselectivity [5] . For large compounds, CYP2J2 metabolism was more restricted to a single site, compared with CYP3A4, which metabolized substrates at multiple sites [5] . A study of microsomes from human livers and human small intestines investigated the metabolism of astemizole by CYP2J2 [6] . This study found that the CYP2J2 substrates arachidonic acid (AA) and ebastine strongly inhibited astemizole O-demethylation in microsomes from human small intestines and in in-vitro experiments with recombinant CYP2J2 [6] . A follow-up study found an inhibition of α-naphthoflavone, ketoconazole, troglitazone, tranylcypromine, ebastine, and terfenadine on the rate of astemizole Odemethylation in human small intestinal microsomes and on the rate of astemizole Odemethylation in recombinant CYP2J2 microsomes [7] .
shown to be cardioprotective after ischemia [11] and after doxorubicin treatment [12] in animal studies using a transgenic mouse model over-expressing the human CYP2J2 isoform. How these findings translate into humans needs to be investigated further. CYP2J2 activates the nuclear peroxisome proliferator-activated receptor α, a controller of lipid metabolism and inflammation, in vitro and in vivo [13] .
A CYP2J2 cDNA was cloned in 1996 by Wu et al. [14] , and the CYP2J2 genomic region was cloned in 2002 by King et al. [8] . CYP2J2 was mapped to human chromosome 1 [1] and the genomic region spans approximately 40 kb [8] , encoding a 1.9 kb transcript from which a 502 amino acid protein with a molecular mass of 57.7 kDa was produced [14] . The CYP2J2 gene, like other CYP2 family genes, is composed of nine exons and eight introns [8] . Four binding site consensus sequences for the SP1 transcription factor are found in the wild-type CYP2J2 promoter [2] . As expected for members of the CYP family, there is a heme-binding motif in the CYP2J2 predicted protein sequence [14] . The presence of CYP2J2 protein in microsomes [14] is indicative of its subcellular localization to the endoplasmic reticulum. CYP2J2 is expressed at high levels in the heart, particularly in cardiac myocytes and endothelial cells in coronary arteries [14, 15] . Other tissues, including the liver, kidney, lung, pancreas, and gastrointestinal tract, also express CYP2J2 [8] . CYP2J2 showed selective distribution in different brain regions [16, 17] . All of these tissues also exhibit fetal expression of CYP2J2 [18] .
Owing to its predicted role in cardiovascular health, CYP2J2 has been extensively studied. The role of CYP2J2 in cancer is also being investigated. In-vitro experiments showed a high and selective expression of CYP2J2 in different human tumor tissues and cell lines [19] . Inhibitors of CYP2J2 related to the drug terfenadine showed effectiveness as antitumor agents in in-vitro assays and in murine xenograft models [20] . Increased CYP2J2 expression has been observed in tumor samples from patients with advanced epithelial ovarian cancer [21] ; and in-vitro studies showed that overexpression of CYP2J2 promoted human cancer metastasis [22] .
Important variants: CYP2J2: G-50T, CYP2J2: G-76T, rs890293, defining single nucleotide polymorphism for CYP2J2*7
Several CYP2J2 variants have been characterized [4, 8, 18] . The Human Cytochrome P450 Nomenclature Committee recognizes 10 CYP2J2 alleles on its website (http://cypalleles.ki.se). By far, the best studied of these is CYP2J2*7, which was first identified by King et al. [8] in a sequencing project to identify CYP2J2 variants. CYP2J2*7 is the most commonly known functional CYP2J2 variant, occurring at frequencies of 2.1-17% (Table 1 ). The defining single nucleotide polymorphism (SNP) for CYP2J2*7, rs890293, is located in the proximal promoter of CYP2J2, substituting 'T' for 'G' found in the wild-type gene [8] . This SNP, located 76 nucleotides upstream of the first nucleotide of the translation start codon and 50 nucleotides upstream of the transcription start site, disrupts a binding site for the SP1 transcription factor [2, 8] . In-vitro assays showed that transcription was reduced to 50% in CYP2J2*7 promoter-reporter gene constructs relative to that observed for the wild-type CYP2J2 promoter [2] .
As CYP2J2*7 is the most common functional CYP2J2 polymorphism discovered, many studies have looked for associations between CYP2J2*7 and various diseases and phenotypes. However, because of conflicting results from different studies, there is no clear consensus on the in-vivo effects of CYP2J2*7 yet. Several clinical studies investigated the association of CYP2J2*7 with different cardiovascular and cerebrovascular diseases. The findings are summarized in Table 2 .
In addition, a case-control study of a predominately Caucasian population found two CYP2J2 intronic tag SNPs, rs10889160 and rs11572325, associated with increased risk of myocardial infarction [37] . Both the SNPs were in moderate linkage disequilibrium with the CYP2J2*7 allele. Interestingly, rs4388726, the tag SNP in the strongest linkage disequilibrium with the CYP2J2*7 polymorphism, showed no significant association with myocardial infarction [37] . This study found no association between these genetic variations in CYP2J2 and ischemic stroke [37] .
Other CYP2J2 alleles
Recombinant CYP2J2 proteins individually engineered to contain the polymorphisms seen in CYP2J2*2, CYP2J2*3, and CYP2J2*6 each exhibited reduced metabolism of AA and LA [8] . Recombinant protein carrying CYP2J2*4 polymorphism showed reduced metabolism of AA only [8] . CYP2J2*5 recombinant protein produced wild-type levels of AA and LA metabolites [8] . Recombinant CYP2J2*8 almost showed a complete loss of enzymatic activity as determined by CYP2J2-catalyzed astemizole O-demethylation and ebastine hydroxylation, whereas recombinant CYP2J2*9 showed enzymatic activities comparable with wild-type CYP2J2 [4] . CYP2J2*10, documented in only one individual, is hypothesized to encode a reduced-function protein [18] . 
